A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: SC Mosunetuzumab
DRUG: IV Glofitamab
DRUG: Iberdomide
DRUG: Golcadomide
DRUG: Obinutuzumab
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche